Cancer immunotherapy gets the energy source of PIP

Researchers are focusing on improving several major areas of cancer immunotherapy

Their research results were published in the journal "Cell Chemical Biology", entitled " Targeted epigenetic induction of mitochondrial biogenesis enhances antitumor immunity in mouse model "

The researchers wrote: "Considering the potential of combination therapy in overcoming the current limitations of cancer immunotherapy, there is an increasing need for small molecule modulators that recognize immune cells that can enhance programmed cell death protein 1 (PD- 1) The effect of the blockade, which leads to better cancer treatment

"Although epigenetic drugs have shown potential in combination therapy, the lack of sequence specificity is a major problem

Molecules expressed by cancer cells can target receptors and inactivate anti-cancer T cells

One of the main reasons is that these patients have insufficient number of T cells and become tired because they do not have enough active research mitochondria

Researchers are trying to increase the mitochondria in T cells to improve the response of cancer patients to PD-1 blockade monotherapy

To overcome this challenge, the researchers used a compound called pyridine-imidazole polyamide (PIP), which can be programmed for specific DNA sequences

The researchers observed in the laboratory that EnPGC-1 activated the mitochondria of mouse T cells

Pandian added: "Before this method can be used in clinical trials, further improvements are needed